Literature DB >> 29846081

Recent advances in CDK inhibitors for cancer therapy.

Amy B Heptinstall1, Iws Adiyasa1, Céline Cano1, Ian R Hardcastle1.   

Abstract

Inhibition of CDKs is an attractive approach to cancer therapy due to their vital role in cell growth and transcription. Pan-CDK inhibitors have shown some clinical benefit, and trials are ongoing. Selective CDK4 and CDK6 inhibitors have been licensed for the treatment of hormone responsive, RB-positive breast cancer in combination with antihormonal agents. Selective inhibitors of CDKs 5, 7, 8, 9 and 12 have been identified across a range of chemotypes.

Entities:  

Keywords:  cancer; cell-cycle; cyclin kinase inhibitor; cyclin-dependent kinase

Mesh：

Substances：

Year:  2018        PMID： 29846081     DOI： 10.4155/fmc-2017-0246

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


  9 in total

Review 1.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

2.  Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.

Authors:  Shuzhen Li; Hua Li; Yajie Cao; Haiying Geng; Fu Ren; Keyan Li; Chunmei Dai; Ning Li
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 3.  A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors.

Authors:  Mariane Teodoro Fernandes; Jacob J Adashek; Carmelia Maria Noia Barreto; Ana Cláudia Barbin Spinosa; Barbara de Souza Gutierres; Gilberto Lopes; Auro Del Giglio; Pedro Nazareth Aguiar
Journal:  Drugs Context       Date:  2018-11-05

4.  Downstream Neighbor of Son Overexpression is Associated With Breast Cancer Progression and a Poor Prognosis.

Authors:  Yufeng Qi; Haodong Wu; Conghui Liu; Danni Zheng; Congzhi Yan; Wenjing Hu; Xiaohua Zhang; Xuanxuan Dai
Journal:  J Breast Cancer       Date:  2022-06-13       Impact factor: 2.922

Review 5.  Targeting Protein Kinases Degradation by PROTACs.

Authors:  Fei Yu; Ming Cai; Liang Shao; Jihong Zhang
Journal:  Front Chem       Date:  2021-06-30       Impact factor: 5.221

6.  Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control.

Authors:  Xin Wang; Kaiyuan Deng; Cheng Wang; Yao Li; Tianqi Wang; Zhi Huang; Yakun Ma; Peiqing Sun; Yi Shi; Shengyong Yang; Yan Fan; Rong Xiang
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

7.  LINC00511 influences cellular proliferation through cyclin-dependent kinases in papillary thyroid carcinoma.

Authors:  Jingjing Xiang; Yaoyao Guan; Adheesh Bhandari; Erjie Xia; Jialiang Wen; Ouchen Wang
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

8.  The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer.

Authors:  Dianne J Beveridge; Kirsty L Richardson; Michael R Epis; Rikki A M Brown; Lisa M Stuart; Andrew J Woo; Peter J Leedman
Journal:  Sci Rep       Date:  2021-09-09       Impact factor: 4.379

Review 9.  Targeting CDK4/6 for Anticancer Therapy.

Authors:  Jiating Qi; Zhuqing Ouyang
Journal:  Biomedicines       Date:  2022-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.